FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220853018> ?p ?o ?g. }

• W4220853018 endingPage "e004157" @default.
• W4220853018 startingPage "e004157" @default.
• W4220853018 abstract "Anti-COVID-19 vaccination may have functional implications for immune checkpoint inhibitor treatment in patients with cancer. This study was undertaken to determine whether the safety or efficacy of anti-PD-1 therapy is reduced in patients with cancer during COVID-19 vaccination. A large multicenter observational study was conducted in 83 Chinese hospitals between January 28, 2021 and September 30, 2021. A total of 3552 patients were screened and 2048 eligible patients with cancer receiving PD-1 inhibitor treatment were recruited. All enrolled patients had received camrelizumab treatment alone or in conjunction with other cancer therapies. Among these, 1518 (74.1%) patients received the BBIBP-CorV vaccine and were defined as the vaccinated subgroup. The remaining 530 (25.9%) patients did not receive anti-COVID-19 vaccination and were defined as the non-vaccinated subgroup. For all participants, Response Evaluation Criteria in Solid Tumor and Common Terminology Criteria for Adverse Events criteria were used to evaluate the efficacy and safety of camrelizumab treatment, respectively. Propensity score match analysis with the optimal pair matching was used to compare these criteria between the vaccinated and non-vaccinated subgroups. A total of 2048 eligible patients with cancer were included (median age 59 years, 27.6% female). Most patients (98.8%) had metastatic cancer of the lung, liver or intestinal tract. Aside from the PD-1 inhibitor treatment, 55.9% of patients received additional cancer therapies. 1518 (74.1%) patients received the BBIBP-CorV vaccine with only mild side effects reported. The remaining patients did not receive COVID-19 vaccination and had a statistically greater percentage of comorbidities. After matching for age, gender, cancer stage/types, comorbidity and performance status, 1060 patients (530 pairs) were selected for propensity score match analysis. This analysis showed no significant differences in overall response rate (25.3% vs 28.9%, p=0.213) and disease control rate (64.6% vs 67.0%, p=0.437) between vaccinated and non-vaccinated subgroups. Immune-related adverse events (irAEs) were reported in both subgroups after camrelizumab treatment. Among vaccinated patients who experienced irAEs, the median interval between the first dose of camrelizumab treatment and the first vaccine shot was ≤16 days. Compared with the non-vaccinated subgroup, irAEs in vaccinated patients were more frequently reported as mild (grade 1 or 2 irAEs; 33.8% vs 19.8%, p<0.001) and these patients were less likely to discontinue the PD-1 inhibitor treatment (4.2% vs 20.4%, p<0.001). Severe irAEs (grade 3 irAE or higher) related to camrelizumab treatment were reported, however no significant differences in the frequency of such events were observed between the vaccinated and non-vaccinated subgroups. The COVID-19 vaccine, BBIBP-CorV, did not increase severe anti-PD-1-related adverse events nor did it reduce the clinical efficacy of camrelizumab in patients with cancer. Thus, we conclude that patients with cancer need not suspend anti-PD-1 treatment during COVID-19 vaccination." @default.
• W4220853018 created "2022-04-03" @default.
• W4220853018 creator A5000980235 @default.
• W4220853018 creator A5001067336 @default.
• W4220853018 creator A5001218798 @default.
• W4220853018 creator A5021384155 @default.
• W4220853018 creator A5035681429 @default.
• W4220853018 creator A5041157505 @default.
• W4220853018 creator A5044825014 @default.
• W4220853018 creator A5048248259 @default.
• W4220853018 creator A5062837781 @default.
• W4220853018 creator A5069879012 @default.
• W4220853018 creator A5081263864 @default.
• W4220853018 creator A5083330096 @default.
• W4220853018 creator A5090815103 @default.
• W4220853018 date "2022-03-01" @default.
• W4220853018 modified "2023-10-03" @default.
• W4220853018 title "Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study" @default.
• W4220853018 cites W2019607817 @default.
• W4220853018 cites W2283585178 @default.
• W4220853018 cites W2890663189 @default.
• W4220853018 cites W2902268061 @default.
• W4220853018 cites W2998269674 @default.
• W4220853018 cites W3092766467 @default.
• W4220853018 cites W3132886187 @default.
• W4220853018 cites W3133745688 @default.
• W4220853018 cites W3145657260 @default.
• W4220853018 cites W3158078097 @default.
• W4220853018 cites W3183003513 @default.
• W4220853018 cites W3184620427 @default.
• W4220853018 cites W3195311678 @default.
• W4220853018 cites W3196715876 @default.
• W4220853018 cites W3198215920 @default.
• W4220853018 cites W3200109370 @default.
• W4220853018 cites W3209203499 @default.
• W4220853018 cites W3210973670 @default.
• W4220853018 cites W4226094308 @default.
• W4220853018 doi "https://doi.org/10.1136/jitc-2021-004157" @default.
• W4220853018 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35264438" @default.
• W4220853018 hasPublicationYear "2022" @default.
• W4220853018 type Work @default.
• W4220853018 citedByCount "15" @default.
• W4220853018 countsByYear W42208530182022 @default.
• W4220853018 countsByYear W42208530182023 @default.
• W4220853018 crossrefType "journal-article" @default.
• W4220853018 hasAuthorship W4220853018A5000980235 @default.
• W4220853018 hasAuthorship W4220853018A5001067336 @default.
• W4220853018 hasAuthorship W4220853018A5001218798 @default.
• W4220853018 hasAuthorship W4220853018A5021384155 @default.
• W4220853018 hasAuthorship W4220853018A5035681429 @default.
• W4220853018 hasAuthorship W4220853018A5041157505 @default.
• W4220853018 hasAuthorship W4220853018A5044825014 @default.
• W4220853018 hasAuthorship W4220853018A5048248259 @default.
• W4220853018 hasAuthorship W4220853018A5062837781 @default.
• W4220853018 hasAuthorship W4220853018A5069879012 @default.
• W4220853018 hasAuthorship W4220853018A5081263864 @default.
• W4220853018 hasAuthorship W4220853018A5083330096 @default.
• W4220853018 hasAuthorship W4220853018A5090815103 @default.
• W4220853018 hasBestOaLocation W42208530181 @default.
• W4220853018 hasConcept C121608353 @default.
• W4220853018 hasConcept C126322002 @default.
• W4220853018 hasConcept C17923572 @default.
• W4220853018 hasConcept C197934379 @default.
• W4220853018 hasConcept C203014093 @default.
• W4220853018 hasConcept C22070199 @default.
• W4220853018 hasConcept C23131810 @default.
• W4220853018 hasConcept C2776256026 @default.
• W4220853018 hasConcept C2777793932 @default.
• W4220853018 hasConcept C71924100 @default.
• W4220853018 hasConceptScore W4220853018C121608353 @default.
• W4220853018 hasConceptScore W4220853018C126322002 @default.
• W4220853018 hasConceptScore W4220853018C17923572 @default.
• W4220853018 hasConceptScore W4220853018C197934379 @default.
• W4220853018 hasConceptScore W4220853018C203014093 @default.
• W4220853018 hasConceptScore W4220853018C22070199 @default.
• W4220853018 hasConceptScore W4220853018C23131810 @default.
• W4220853018 hasConceptScore W4220853018C2776256026 @default.
• W4220853018 hasConceptScore W4220853018C2777793932 @default.
• W4220853018 hasConceptScore W4220853018C71924100 @default.
• W4220853018 hasFunder F4320326177 @default.
• W4220853018 hasIssue "3" @default.
• W4220853018 hasLocation W42208530181 @default.
• W4220853018 hasLocation W42208530182 @default.
• W4220853018 hasLocation W42208530183 @default.
• W4220853018 hasLocation W42208530184 @default.
• W4220853018 hasOpenAccess W4220853018 @default.
• W4220853018 hasPrimaryLocation W42208530181 @default.
• W4220853018 hasRelatedWork W2092016588 @default.
• W4220853018 hasRelatedWork W2396000345 @default.
• W4220853018 hasRelatedWork W2795791984 @default.
• W4220853018 hasRelatedWork W2917189641 @default.
• W4220853018 hasRelatedWork W3023923059 @default.
• W4220853018 hasRelatedWork W4281286690 @default.
• W4220853018 hasRelatedWork W4312375361 @default.
• W4220853018 hasRelatedWork W4385077270 @default.
• W4220853018 hasRelatedWork W71670329 @default.
• W4220853018 hasRelatedWork W2186274372 @default.
• W4220853018 hasVolume "10" @default.

• next